Sumitomo Mitsui Trust Group Inc. Grows Position in DaVita Inc. $DVA

Sumitomo Mitsui Trust Group Inc. increased its stake in DaVita Inc. (DVA) by 4.0% in Q2, contributing to institutional investors holding 90.12% of the company, despite recent financial performance. DaVita reported Q3 EPS of $2.51, significantly missing analyst estimates of $3.29, though revenue grew 4.8% year-over-year, and provided FY2025 EPS guidance of $10.35-$11.15. Analyst sentiment is largely cautious, with multiple firms issuing "Hold" or "Underperform" ratings and reducing price targets, resulting in an average "Reduce" rating and a consensus price target of $153.25, while the stock recently opened at $126.25.

Analysis

DaVita Inc. (DVA) reported a significant earnings miss for Q3, with EPS of $2.51 falling notably short of the $3.29 analyst consensus, despite a 4.8% year-over-year revenue increase. The company has issued FY2025 EPS guidance ranging from $10.35 to $11.15, which aligns closely with current sell-side predictions of $10.76 for the year.

Analyst sentiment remains largely cautious to negative, evidenced by multiple price target reductions from firms like Barclays and Bank of America, which now rate the stock "equal weight" or "underperform." The stock carries an average "Reduce" rating and a consensus price target of $153.25, which stands considerably above its recent opening price of $126.25.

Despite the recent earnings disappointment and subdued analyst outlook, institutional investors maintain a significant stake, collectively owning 90.12% of the company. Sumitomo Mitsui Trust Group Inc. notably increased its Q2 holdings by 4.0%, acquiring an additional 4,404 shares, suggesting continued institutional interest even as the stock trades near its one-year low of $122.93 and below its 50-day and 200-day moving averages.

Key Decisions for Investors

• Investors should exercise caution given the significant Q3 EPS miss and the prevailing negative analyst sentiment, monitoring for signs of operational improvement.
• Consider the discrepancy between the current stock price ($126.25) and the consensus price target ($153.25) as a potential long-term entry point, but only after conducting thorough due diligence on the drivers of the earnings shortfall.
• Watch for future guidance updates and competitive landscape shifts within the kidney dialysis sector to assess the sustainability of DaVita's business model and its ability to meet FY2025 EPS targets.